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Introduction {#jdi12531-sec-0001}
============

Programmed cell death‐1 (PD‐1) is expressed on T cells, B cells and macrophages, and negatively regulates immune responses by binding to PD‐1 ligands (PD‐L1 or PD‐L2). Most cancers escape from the host immune system as a result of the presence of those ligands. Nivolumab is a monoclonal antibody against the PD‐1 receptor, achieving disinhibition of tumor‐specific immune responses[1](#jdi12531-bib-0001){ref-type="ref"}. Although such immune checkpoint inhibitors have been shown to be highly useful against several types of cancer, descriptions of endocrinological adverse events have been accumulating. Some reports have described new‐onset diabetes after anti‐PD‐1 pharmacotherapy[2](#jdi12531-bib-0002){ref-type="ref"}, [3](#jdi12531-bib-0003){ref-type="ref"}, [4](#jdi12531-bib-0004){ref-type="ref"}, [5](#jdi12531-bib-0005){ref-type="ref"}, but the evidence remains limited. We describe herein the case of a woman who developed fulminant type 1 diabetes during anti‐PD‐1 therapy, with some important findings that should contribute to elucidation of the pathogenesis.

Case Report {#jdi12531-sec-0002}
===========

A 55‐year‐old Japanese woman receiving nivolumab (2 mg/kg, once every 3 weeks) for malignant melanoma was referred to the Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University Hospital, Oita, Japan, as a result of hyperglycemia. She had no history of diabetes and no evidence of pancreatic metastases. She had been receiving nivolumab without combination with anti‐T lymphocyte‐associated antigen 4 antibody for 12 months at the time of referral, after 1 year of chemotherapy with dacarbazine, nimustine, cisplatin and tamoxifen. Blood glucose levels had been normal until the last blood examination, which was carried out 3 weeks before her referral. Although marked hyperglycemia (580 mg/dL) and ketonuria had been noted at the first visit to our department, hemoglobin A1c level was relatively low (7.0%), suggesting rapid onset. The short period from onset to ketosis, extreme hyperglycemia and relatively low hemoglobin A1c level suggested fulminant type 1 diabetes[6](#jdi12531-bib-0006){ref-type="ref"}. Findings at onset, such as serum C‐peptide level (1.0 ng/mL) and urinary C‐peptide excretion (12.6 μg/day), did not meet the diagnostic criteria for fulminant type 1 diabetes, but serum C‐peptide levels dropped to below the limit of detection over the next 2 weeks, and glucagon tolerance testing showed complete depletion of insulin. As treatment for fulminant type 1 diabetes, multiple daily injections of insulin were started. Negative results were obtained for all islet autoantibodies (glutamic acid decarboxylase, insulinoma‐associated antigen‐2, insulin autoantibodies and zinc transporter 8), and further investigation revealed the DRB1\*04:05‐DQB1\*04:01 human leukocyte antigen (HLA) haplotype, which is strongly associated with autoimmune type 1 diabetes in Japan[7](#jdi12531-bib-0007){ref-type="ref"}. No blood examination findings or symptoms suggested acute viral infection before onset, and pancreatic enzyme levels at onset were not elevated (Table [1](#jdi12531-tbl-0001){ref-type="table-wrap"}). Computed tomography showed mild atrophy of the pancreas, and endoscopic ultrasonography showed several findings generally seen in early chronic pancreatitis, namely hyperechoic foci and strands, lobularity, and cysts. Although those findings are often seen among individuals with heavy intake of alcohol, the patient had no history of drinking. Nivolumab treatment was resumed 1 month after the patient\'s referral, and no further side‐effects have been observed to date. Islet autoantibodies have remained negative, and insulin secretion has remained depleted as of 3 months after onset. Treatment with multiple insulin injections is ongoing.

###### 

Laboratory results of the patient

                                                         Results
  ------------------------------------------------------ ---------------
  Glucagon (pg/mL)                                       134 (70--174)
  Amylase (U/L)                                          36 (37--125)
  Elastase1 (ng/dL)                                      93 (\<300)
  Lipase (IU/L)                                          31 (11--53)
  Thyroid‐stimulating hormone receptor antibody (IU/L)   \<1.0 (\<2.0)
  Thyroglobulin antibody (IU/mL)                         10.9 (\<28)
  Thyroid peroxidase antibody (IU/mL)                    5.9 (\<16)
  Antipituitary antibody                                 (--)
  Antinuclear antibody                                   (--)
  Time‐series data of serum CPR (ng/mL)                  (0.61--2.09)
  Day 0                                                  1.0
  Day 2                                                  0.7
  Day 7                                                  0.3
  Day 17                                                 \<0.1

Normal ranges given in parentheses where appropriate. CPR, C‐peptide.
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Discussion {#jdi12531-sec-0003}
==========

The present report described a case of new‐onset diabetes with anti‐PD‐1 therapy that showed a rapid fall into insulin‐dependence. Onset was considered to be associated with the pharmacotherapy, as no other potential factors or causes (e.g., family history, irregular lifestyle, viral infection, pancreatic metastasis of the cancer or drugs other than nivolumab) could be identified. Our search of the literature found four reports (8 cases) of onset or worsening of diabetes in association with anti‐PD‐1 therapies (not limited to nivolumab), and all except one of those cases presented with diabetic ketoacidosis or ketonuria followed shortly thereafter by insulin‐dependence[2](#jdi12531-bib-0002){ref-type="ref"}, [3](#jdi12531-bib-0003){ref-type="ref"}, [4](#jdi12531-bib-0004){ref-type="ref"}, [5](#jdi12531-bib-0005){ref-type="ref"}. Considering the rapid onset, severity and potential mortality of those situations, routine measurement of both hemoglobin A1c and blood glucose levels is warranted after starting administration of anti‐PD‐1 antibodies. In the present case, we might have observed the very early stage of fulminant type 1 diabetes, considering that the patient was not completely insulin‐dependent for the first few days after onset.

In the present case, all results for islet autoantibodies were negative. Half of the previously reported patients who developed insulin‐dependent diabetes after anti‐PD‐1 therapy likewise showed no detectable autoantibodies (Table [2](#jdi12531-tbl-0002){ref-type="table-wrap"}). The pathogenesis in these patients thus seems to differ at least partly from that of conventional autoimmune type 1 diabetes involving islet autoantibodies. Ansari *et al*.[8](#jdi12531-bib-0008){ref-type="ref"} found no correlation between insulin autoantibody levels and development of diabetes with blockade of the PD‐1--PD‐L1 pathway in mice, and some mice developed diabetes despite the apparent absence of autoantibodies.

###### 

Summary of previous reports

  Case no.   Literature                                                       Age/sex (ethnicity)   Primary diagnosis                                Pertinent history                      Anti‐PD‐1 drug    Other chemotoxins                              Preceding viral infection   Diabetes presentation                 CPR and glucose             Time after anti‐PD‐1              Islet cell autoantibodies               HLA
  ---------- ---------------------------------------------------------------- --------------------- ------------------------------------------------ -------------------------------------- ----------------- ---------------------------------------------- --------------------------- ------------------------------------- --------------------------- --------------------------------- --------------------------------------- ----------------------------------------
  1          Okamoto *et al*.                                                 55 F (Japanese)       Malignant melanoma                               Dyslipidemia gastric ulcer             Nivolumab         Dacarbazine, nimustine, cisplatin, tamoxifen   (--)                        Ketonuria 580 mg/dL HbA1c 7.0%        1.0 ng/dL and 580 mg/dL     12 months                         GAD (--) ICA (--) IA‐2 (--) ZnT8 (--)   DRB1\*04:05, DQB1\*04:01
  2          Hughes *et al*.[4](#jdi12531-bib-0004){ref-type="ref"}           55 F (Not listed)     Malignant melanoma                               Autoimmune thyroid disease             Nivolumab         Ipilimumab, prednisone                         Not listed                  DKA 532 mg/dL HbA1c 6.9%              \<0.1 ng/dL and 52 mg/dL    5 months                          None                                    A2.1+, DR4+
  3          Hughes *et al*.[4](#jdi12531-bib-0004){ref-type="ref"}           83 F (Not listed)     Non‐small‐cell lung cancer                       Remote smoker                          Nivolumab         None                                           Not listed                  DKA 350 mg/dL HbA1c 7.7%              \<0.1 ng/dL and 336 mg/dL   \<1 month                         GAD (+)                                 A2.1+, DR4+
  4          Hughes *et al*.[4](#jdi12531-bib-0004){ref-type="ref"}           63 M (Not listed)     Renal cell cartinoma                             Hypertension                           Nivolumab         Proleukin, bevacizumab, interferon             Not listed                  Random glucose 247 mg/dL HbA1c 8.2%   1.3 ng/dL and 79 mg/dL      4 months                          GAD (+) ICA (+) IAA (+)                 A2.1+, DR4+
  5          Hughes *et al*.[4](#jdi12531-bib-0004){ref-type="ref"}           58 M (Not listed)     Small‐cell lung cancer                           Type 2 diabetes mellitus               Nivolumab         Carboplatin/etoposide, paclitaxel              Not listed                  DKA 749 mg/dL HbA1c 9.7%              \<0.1 ng/dL and 284 mg/dL   1 week                            GAD (+)                                 A2.1+
  6          Hughes *et al*.[4](#jdi12531-bib-0004){ref-type="ref"}           64 F (Not listed)     Malignant melanoma                               Autoimmune thyroid disease psoriasis   Pembrolizumab     None                                           Not listed                  Ketonuria 703 mg/dL HbA1c 7.4%        0.5 ng/dL and 268 mg/dL     \<1 month                         None                                    DR4+
  7          Martin‐Liberal *et al*.[3](#jdi12531-bib-0003){ref-type="ref"}   54 F (Not listed)     Malignant melanoma                               Asthma                                 Pembrolizumab     Ipilimumab                                     Not listed                  DKA BS, HbA1c: not shown              Not listed                  6 weeks (after three infusions)   GAD (+) ICA (--) IAA (--)               DRB1\*04, DQB1\*03:02 (HLA A2 DR4 DQ8)
  8          Mellati *et al*.[2](#jdi12531-bib-0002){ref-type="ref"}          70 M (Not listed)     Adenocarcinoma of the lung                       Not listed                             (Anti‐PD‐L1 Ab)   Not listed                                     Not listed                  DKA 411 mg/dL HbA1c 9.8%              0.3 ng/dL and 411 mg/dL     15 weeks                          GAD (--) IAA (--)                       Not listed
  9          Mellati *et al*.[2](#jdi12531-bib-0002){ref-type="ref"}          66 F (Not listed)     Sarcomatoid squamous cell carcinoma of the jaw   Not listed                             Anti‐PD‐1 Ab      Not listed                                     Not listed                  DKA 752 mg/dL HbA1c 9.4%              \<0.1 ng/dL and 752 mg/dL   7 weeks                           GAD (+) ICA (--) IAA (--) ZnT8 (--)     DR3‐DQ2/DR4‐DR8
  10         Gaudy *et al*.[5](#jdi12531-bib-0005){ref-type="ref"}            44 F (Caucasian)      Malignant melanoma                               Autoimmune thyroid disease             Pembrolizumab     Ipilimumab                                     (--)                        DKA 908 mg/dL HbA1c 6.85%             Undetectable                5 weeks                           GAD (--) ICA (--)                       Not listed

Ab, antibodies; CPR, C‐peptide; DKA, diabetic ketoacidosis; F, female; GAD, glutamic acid decarboxylase; HbA1c, hemoglobin A1c; HLA, human leukocyte antigen; IA‐2, insulinoma‐associated antigen‐2; IAA, insulin autoantibody; ICA, islet cell antibody; M, male; PD‐1, programmed cell death‐1; PD‐L1, programmed cell death ligand‐1; ZnT8, zinc transporter 8.
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In contrast, reduced activity of PD‐1 is apparently common to both conventional autoimmune type 1 diabetes and anti‐PD‐1 therapy‐related diabetes. Fujisawa *et al*.[9](#jdi12531-bib-0009){ref-type="ref"} recently showed a reduction in PD‐1 expression on T cells in type 1 diabetes compared with other types of diabetes. Perri *et al*.[10](#jdi12531-bib-0010){ref-type="ref"} also suggested that lower expression of PD‐1 on T cells causes inappropriate activation of those cells in insulin‐dependent diabetes. Anti‐PD‐1 drugs could produce a similar situation, and PD‐1 reduction might cause inappropriate activation of T cells resulting in autoimmune responses against pancreatic β‐cells.

Human leukocyte antigen typing in this case showed haplotype DRB1\*04:05‐DQB1\*04:01, which is the haplotype most closely associated with autoimmune or fulminant type 1 diabetes in Japan[7](#jdi12531-bib-0007){ref-type="ref"}. Reported cases to date have also shown high‐risk HLA genotypes for autoimmune diabetes (Table [2](#jdi12531-tbl-0002){ref-type="table-wrap"}). Considering these findings, HLA could be involved in the onset of insulin‐dependent diabetes with anti‐PD‐1 therapy. Autoimmune diabetes might develop when anti‐PD‐1 drugs are given to at‐risk patients, through imbalanced activation and inhibition of T cells, although the underlying mechanisms remain unclear. Biomarkers predictive of anti‐PD‐1 therapy‐related diabetes have yet to be clarified, but HLA haplotypes could be one such biomarker. Further accumulation of cases and evidence is required.

Anti‐PD‐1 therapy can cause insulin‐dependent diabetes that develops and progresses rapidly in a manner differing from conventional autoimmune diabetes, possibly through inappropriate activation of T cells. These cases might not present with autoantibodies to islet cells. HLA haplotypes might be related to disease onset. Physicians should be aware of this serious adverse event, and carry out routine blood testing during anti‐PD‐1 therapy. Further studies are required to elucidate the pathogenesis and background factors for this form of diabetes.
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